FIGURE 2. Protective efficacy of heterologous rAd prime-boost vaccine regimens.
From the following article:
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
Jinyan Liu, Kara L. O'Brien, Diana M. Lynch, Nathaniel L. Simmons, Annalena La Porte, Ambryice M. Riggs, Peter Abbink, Rory T. Coffey, Lauren E. Grandpre, Michael S. Seaman, Gary Landucci, Donald N. Forthal, David C. Montefiori, Angela Carville, Keith G. Mansfield, Menzo J. Havenga, Maria G. Pau, Jaap Goudsmit & Dan H. Barouch
Nature 457, 87-91(1 January 2009)
doi:10.1038/nature07469
Monkeys were challenged intravenously with SIVMAC251, and protective efficacy was monitored by SIV RNA levels (a, b), CD4+ T lymphocyte counts (c), and clinical disease progression and mortality (d) after challenge. Viral loads are depicted longitudinally for each group (a), and peak (day 14) and setpoint (day 112–420) viral loads are summarized for each group (b). Asterisks indicate mortality. Comparisons among groups were performed by two-sided Wilcoxon's rank-sum (a, b) and Fisher's exact (d) tests.
Download file
If the slide opens in your browser, select "File > Save As" to save it.
Download Power Point slide (654K)Slides may be downloaded for educational use, according to the terms described in Nature Publishing Group's licensing policy.
BACK TO ARTICLE